Chirodoc, as you know, I am new on this thread and this stock. It seems very interesting, and especially feel so after reading a few of Tom D.'s convincing posts.
But I still have the following questions that have not been answered. I'd appreciate if you or anybody else can help me out.
1. The ODAC meeting on Dec. 18 does not grant the full right for Depo to sell the drugs, does it ? What other FDA approval procedure is required ? Per Tom, it seems the ODAC approval is a non challenge. The challenge seems more with FDA process, after the ODAC meeting. What is this thread's opinion in turns of the chance to get full FDA approval, especially given the disappointing experience from one of Depo's competitor ?
2. After Chirodoc recommended this stock to me from the CKFR thread, I did a lot of research tonight. One thing I found about DEPO is its heavy inside trading during the last two years. E. Erickson, the president, dumped 22,500 shares as lately as on July 30, 1997; Director Roger Davisson sold a total of 729,817 shares during the last two years although he also bought 20,030 shares (option ?). Other names on the inside sale list include Dana McGovan (CEO, small amount), Sinil Kim (VP, very active seller), Alta VLP (>500,000 shares), Fred Middleton (CB), Steohen Howell (VP), David Thomas (V), and a few more. And I don't have the inside trading data after July 97.
I am wondering, if this DepoCyt is indeed this promising. Does this alarm anybody ?
I do not mean to sound negative or something. I am still very interested in this stock. The analyst opinion and the earning/revenue estimate looks great for a $15 biotech stock. But I like to know the true reality before I tie up my limited financial resources into any stock.
Thanks. |
